First Affiliated Hospital of Soochow University
苏州大学附属第一医院
Listed for 29 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at First Affiliated Hospital of Soochow University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌8 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌22 papers led
- Hepatocellular carcinoma肝细胞癌73 papers led
- Stomach cancer胃癌90 papers led2 open trials led
- Retinoblastoma视网膜母细胞瘤2 papers led
- Chordoma脊索瘤2 papers led
- Osteosarcoma骨肉瘤4 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤6 papers led
- Neuroblastoma神经母细胞瘤1 paper led
- Multiple myeloma多发性骨髓瘤27 papers led7 open trials led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病12 papers led10 open trials led
- Aplastic anaemia再生障碍性贫血11 papers led2 open trials led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症6 papers led2 open trials led
- Beta thalassaemiaβ 地中海贫血1 paper led
- Haemophilia A血友病 A6 papers led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜5 papers led1 open trial led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病10 papers led
- Myasthenia gravis重症肌无力9 papers led
- Moyamoya disease烟雾病3 papers led
- Wilson disease肝豆状核变性(Wilson 病)2 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
- Spinal muscular atrophy脊髓性肌萎缩症0 papers led
- Fabry disease法布雷病3 papers led
- Duchenne muscular dystrophy杜氏肌营养不良2 papers led
- Behçet disease白塞病0 papers led
- IgA nephropathyIgA 肾病2 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
- Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
Not listed for: Hepatoblastoma, Ewing sarcoma, Atypical haemolytic uraemic syndrome, Fanconi anaemia, IgG4-related disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 8 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Suzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led8
- Expression and functional implications of YME1L in nasopharyngeal carcinoma.
- Prognostic modeling for nasopharyngeal carcinoma (NC) undergoing concurrent chemoradiotherapy using clinical and enhanced MRI-Delta radiomics data: A preliminary study.
- Syncope as the initial symptom in a patient with nasopharyngeal carcinoma: a case report.
- Overexpressed Gαi1 exerts pro-tumorigenic activity in nasopharyngeal carcinoma.
- CircKIAA0368 Promotes Proliferation, Migration, and Invasion by Upregulating HOXA10 in Nasopharyngeal Carcinoma.
- Let-7i-5p promotes a malignant phenotype in nasopharyngeal carcinoma via inhibiting tumor-suppressive autophagy.
- Key genes affecting the progression of nasopharyngeal carcinoma identified by RNA-sequencing and bioinformatic analysis.
- Continuous quality improvement of nutrition management during radiotherapy in patients with nasopharyngeal carcinoma.
More papers found outside PubMed (not counted)13
- Salivary metabolomic profiling reveals dynamic metabolic adaptations in nasopharyngeal carcinoma (NPC) patients during radiotherapy
- Prediction of Parotid Gland Changes in Radiation-Induced Oral Mucositis of Nasopharyngeal Carcinoma Based on Metabolism-Imaging Bimodal Omics
- Additional file 1 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 2 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 3 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 4 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 5 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 6 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Additional file 7 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy
- Advances of radiotherapy combined with targeted therapy for nasopharyngeal carcinoma
- Efficacy and safety of penpulimab-containing regimens for advanced malignant solid tumors that have failed immunotherapy: A real-world study.
- Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma
- Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 22 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.8%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Suzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led22
- RRP9 Promotes Esophageal Squamous Cell Carcinoma Progression through E2F1 Transcriptional Regulation of CDK1.
- Organoid-based two-step drug screening for rapid identification of chemotherapy-resistant oesophageal squamous cell carcinoma and alternative therapies.
- Correlation of immune cell subsets in the tumor microenvironment and peripheral blood with immunotherapy response in esophageal squamous cell carcinoma.
- Decursin Suppresses Esophageal Squamous Cell Carcinoma Progression via Orchestrated Cell Cycle Deceleration, Apoptotic Activation, and Oncoprotein Degradation.
- A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy with or witho
- Improved circulating tumor DNA identification for detection of esophageal squamous cell carcinoma by enzymatic methyl sequencing and hybrid neural network.
- Explainable semi-supervised model for predicting invasion depth of esophageal squamous cell carcinoma based on the IPCL and AVA patterns.
- Diagnostic Efficacy of Type B Vessels in the Japan Esophageal Society Classification for the Depth of Invasion of Superficial Esophageal Squamous Cell Carcinoma.
- Integrating 18F-FDG PET/CT radiomics and body composition for enhanced prognostic assessment in patients with esophageal cancer.
- First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial.
- Spatial transcriptome profiling identifies DTX3L and BST2 as key biomarkers in esophageal squamous cell carcinoma tumorigenesis.
- A prognostic nomogram for T3N0M0 esophageal squamous cell carcinoma patients undergoing radical surgery based on computed tomography radiomics and inflammatory nutritional biomarkers.
- RGS16 regulates Hippo-YAP activity to promote esophageal cancer cell proliferation and migration.
- Multi-omics analyses reveal spatial heterogeneity in primary and metastatic oesophageal squamous cell carcinoma.
- Peripheral Blood Markers Predictive of Progression-Free Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With PD-1 Inhibitors Plus Chemotherapy as First-Line Therapy.
- Sesamin exerts anti-tumor activity in esophageal squamous cell carcinoma via inhibition of TRIM44 and NF-κB signaling.
- Verbascoside represses malignant phenotypes of esophageal squamous cell carcinoma cells by inhibiting CDC42 via the HMGB1/RAGE axis.
- microRNA-497-mediated Smurf2/YY1/HIF2α axis in tumor growth and metastasis of esophageal squamous cell carcinoma.
- Esophageal carcinosarcoma comprising undifferentiated pleomorphic sarcoma and squamous cell carcinoma: a case report.
- Overcoming radio-resistance in esophageal squamous cell carcinoma via hypermethylation of PIK3C3 promoter region mediated by KDM5B loss.
- Can Lymphovascular Invasion be Predicted by Preoperative Contrast-Enhanced CT in Esophageal Squamous Cell Carcinoma?
- Mechanism and Role of the Neuropeptide LGI1 Receptor ADAM23 in Regulating Biomarkers of Ferroptosis and Progression of Esophageal Cancer.
All its trials on ClinicalTrials.gov, any status3
- Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora
- Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma
- Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
More papers found outside PubMed (not counted)18
- A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy with or witho
- Abstract 1945: High-sensitive gastrointestinal cancers early detection by cell-free DNA targeted methylation sequencing with an innovative modeling approach
- Additional file 1 of A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradio
- ESCC-eCura: A Novel Scoring System to Assess Curability after Endoscopic Submucosal Dissection for Superficial Esophageal Squamous Cell Carcinoma
- Kurarinone's synergistic target space and therapeutic promise for esophageal squamous cell carcinoma are revealed by systems pharmacology
- Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial
- Regulation and function of the RSK family in colorectal cancer
- Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma
- Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma
- Exosomal miR-29b-3p derived from cancer- associated fibroblasts contributes to esophageal squamous cell carcinoma cell progression by NAA60 hypomethylation
- Postoperative Radiotherapy Involving Tumor Bed with or without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial
- LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling
- The preliminary efficacy and safety of KN046 plus concurrent chemoradiation therapy in recurrent and metastatic esophageal squamous cell carcinoma.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 73 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Suzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led73
- Gd-EOB-DTPA-enhanced MRI radiomics and deep learning models for predicting the pathological differentiation degree in hepatocellular carcinoma.
- Functional regulatory roles of HNF1B in promoting cell proliferation, migration, invasion and fate decision of hepatocellular carcinoma.
- Hepatocellular carcinoma (HCC) and focal nodular hyperplasia (FNH) showing iso- or hyperintensity in the hepatobiliary phase: differentiation using Gd-EOB-DTPA enhanced MRI radiomics and deep learning features.
- A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma.
- Construction of an Oxidative Stress Risk Model to Analyze the Correlation Between Liver Cancer and Tumor Immunity.
- Clinical characteristics and risk factors of hepatocellular carcinoma development in Budd-Chiari syndrome patients after endovascular treatment.
- FBXO42 promotes hepatocellular carcinoma progression via mediating p57Kip2 ubiquitination and degradation.
- CircBRWD1 promotes hepatitis B virus replication and hepatocellular carcinoma progression by regulating the miR-513a-5p/TNPO1 axis.
- Survival benefits of different immunotherapies for hepatocellular carcinoma: a meta-analysis highlighting age, gender, etiology, and tumor burden.
- KRT80 in hepatocellular carcinoma plays oncogenic role via epithelial-mesenchymal transition and PI3K/AKT pathway.
- Prexasertib exerts a synergistic effect on the antitumor activity of Lenvatinib through ALOX15-mediated ferroptosis in hepatocellular carcinoma.
- Safety and efficacy of TACE combined with immune checkpoint inhibitors plus molecular targeted therapies in older adults with unresectable hepatocellular carcinoma.
- Transarterial chemoembolization combined with percutaneous ethanol injection for the treatment of hepatocellular carcinoma at high-risk areas.
- Heterogeneity Habitats -Derived Radiomics of Gd-EOB-DTPA Enhanced MRI for Predicting Proliferation of Hepatocellular Carcinoma.
- Deep Learning Radiopathomics Models Based on Contrast-enhanced MRI and Pathologic Imaging for Predicting Vessels Encapsulating Tumor Clusters and Prognosis in Hepatocellular Carcinoma.
- PARK7-driven IGF2BP3-K76 lactylation mediates ferroptosis and HAIC resistance in hepatocellular carcinoma.
- Development and validation of a prealbumin-bilirubin model for prognostic prediction in intermediate hepatocellular carcinoma undergoing transarterial chemoembolization.
- Efficacy and safety of hepatic arterial infusion chemotherapy followed by transarterial embolization for hepatocellular carcinoma.
- Emergent TIPS for acute gastroesophageal variceal bleeding in cirrhotic patients with hepatocellular carcinoma.
- Tim-1-mediated extracellular matrix promotes the development of hepatocellular carcinoma.
- Identification and evaluation of plasma exosome RNA biomarkers for non-invasive diagnosis of hepatocellular carcinoma using RNA-seq.
- Gd-EOB-DTPA enhanced MRI nomogram model to differentiate hepatocellular carcinoma and focal nodular hyperplasia both showing iso- or hyperintensity in the hepatobiliary phase.
- miR-29a-SIRT1-Wnt/β-Catenin Axis Regulates Tumor Progression and Survival in Hepatocellular Carcinoma.
- Long Non-coding RNA LINC00342 Promotes the Proliferation, Invasion, and Migration of Primary Hepatocellular Carcinoma Cells by Regulating the Expression of miRNA-19a-3p, miRNA-545-5p, and miRNA-203a-3p.
- Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8+T Lymphocytes Cytotoxicity in an Orthotopic Hepatocellular Carcinoma Rat Model.
- The Incidences and Related CT Features of Vascular Lake Phenomenon on Angiography Before Chemoembolization.
- Transarterial chemoembolization refractoriness in hepatocellular carcinoma: Chinese College of Interventionalists definition and consensus statement.
- Radiomic Analysis of Contrast-Enhanced CT Predicts Glypican 3-Positive Hepatocellular Carcinoma.
- Cryoablation combined with dual immune checkpoint blockade enhances antitumor efficacy in hepatocellular carcinoma model mice.
- Which risk model can better predict hepatocellular carcinoma in hepatitis B patients with an antiviral treatment duration of over 1 year?
- Berberine inhibits the glycolysis and proliferation of hepatocellular carcinoma cells by down-regulating HIF-1α.
- Machine learning based on gadoxetic acid-enhanced MRI for differentiating atypical intrahepatic mass-forming cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.
- Circular RNA hsa_circ_0005239 contributes to hepatocellular carcinoma cell migration, invasion, and angiogenesis by targeting the miR-34a-5p/PD-L1 axis.
- Cuproptosis-related lncRNAs predict the prognosis and immune response in hepatocellular carcinoma.
- The Role of Oxidative Stress in the Development and Therapeutic Intervention of Hepatocellular Carcinoma.
- Letter re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
- Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study.
- LncRNA NUTM2A-AS1 aggravates the progression of hepatocellular carcinoma by activating the miR-186-5p/KLF7-mediated Wnt/beta-catenin pathway.
- Nomogram Estimating Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma From Preoperative Gadoxetate Disodium-Enhanced MRI.
- Preoperative Diagnosis of Dual-Phenotype Hepatocellular Carcinoma Using Enhanced MRI Radiomics Models.
- LINC00106/RPS19BP1/p53 axis promotes the proliferation and migration of human prostate cancer cells.
- Global profiling of protein lysine lactylation and potential target modified protein analysis in hepatocellular carcinoma.
- Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma.
- hsa_circ_0003410 promotes hepatocellular carcinoma progression by increasing the ratio of M2/M1 macrophages through the miR-139-3p/CCL5 axis.
- Preoperative CECT-based Radiomic Signature for Predicting the Response of Transarterial Chemoembolization (TACE) Therapy in Hepatocellular Carcinoma.
- LINC02535/miR-30a-5p/GALNT3 axis contributes to lung adenocarcinoma progression via the NF- κ B signaling pathway.
- Gd-EOB-DTPA-enhanced MRI radiomics to predict vessels encapsulating tumor clusters (VETC) and patient prognosis in hepatocellular carcinoma.
- Hypothyroidism has a protective causal association with hepatocellular carcinoma: A two-sample Mendelian randomization study.
- Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.
- Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response.
- Comprehensive Analysis on the Specific Role and Function of Mitochondrial Inner Membrane Protein MPV17 in Liver Hepatocellular Carcinoma.
- Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty live
- Re: "Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis".
- Insights into the Allosteric Effect of SENP1 Q597A Mutation on the Hydrolytic Reaction of SUMO1 via an Integrated Computational Study.
- Cytotoxic and anti-tumor effects of 3,4-seco-lupane triterpenoids from the leaves of Eleutherococcus sessiliflorus against hepatocellular carcinoma.
- Immune suppressive function of IL-1α release in the tumor microenvironment regulated by calpain 1.
- Activating transcription factor 2 promotes the progression of hepatocellular carcinoma by inducing the activation of the WHSC1-mediated TOP2A/PI3K/AKT axis.
- Lysine demethylase 5C epigenetically reduces transcription of ITIH1 that results in augmented progression of liver hepatocellular carcinoma.
- Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
- LncRNA PCGEM1 mediates oxaliplatin resistance in hepatocellular carcinoma via miR-129-5p/ETV1 axis in vitro.
- RUFY3 promotes the progression of hepatocellular carcinoma through activating NF-κB-mediated epithelial-mesenchymal transition.
- Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma.
- MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling.
- Integrated I-125 Seed Implantation Combined with Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombus.
- Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.
- CT-based radiomics model to distinguish necrotic hepatocellular carcinoma from pyogenic liver abscess.
- Silencing PFKP restrains the stemness of hepatocellular carcinoma cells.
- Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
- ceRNA network development and tumor-infiltrating immune cell analysis in hepatocellular carcinoma.
- miR-760 mediated the proliferation and metastasis of hepatocellular carcinoma cells by regulating HMGA2.
- cFUT8 promotes liver cancer progression by miR-548c/FUT8 axis.
- Imaging features based on Gd-EOB-DTPA-enhanced MRI for predicting vessels encapsulating tumor clusters (VETC) in patients with hepatocellular carcinoma.
- Correlation of radiomic features on dynamic contrast-enhanced magnetic resonance with microvessel density in hepatocellular carcinoma based on different models.
Chinese-language papers (not in the count)7
- [Diagnosis and differential diagnosis of small hepatocellular carcinoma in the context of cirrhosis].
- [Efficacy and safety of transarterial chemoembolization combined with sintilimab and bevacizumab biosimilar for unresectable hepatocellular carcinoma].
- [Diagnostic value of Gd-EOB-DTPA-enhanced MRI radiomics models for dual-phenotype hepatocellular carcinoma].
- [Construction of a prognostic model for hepatocellular carcinoma based on pyroptosis-related genes].
- [The application value of Gd-EOB-DTPA enhanced MRI based radiomics in the differential diagnosis of iso-or hyperintensity HCC and focal nodular hyperplasia in hepatobiliary phase].
- [The prediction value of enhanced magnetic resonance imaging nomogram model for dual phenotype hepatocellular carcinoma].
- [Value of the application of enhanced CT radiomics and machine learning in preoperative prediction of microvascular invasion in hepatocellular carcinoma].
All its trials on ClinicalTrials.gov, any status6
- Evaluate the Effect of Tirazamine on Primary Liver Cancer.
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
- A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
- The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
- Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation
Cancer
Stomach cancer
胃癌Led 90 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.9%.
3 hospitals in Suzhou for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 5
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingAI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging
- Phase
- Not given
- Started
- 2026-05
- Registry
- NCT07551466
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingVenetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT07012447
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingAI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- Phase
- Not given
- Started
- 2023-09
- Registry
- NCT06035250
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou
- Not yet recruitingLymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07902596
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province Hospital; 6 listed hospitals as study sitesNanjing, Qingdao, Shanghai, Shijiazhuang, Suzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led90
- Integrating narrative therapy and sleep intervention to enhance recovery, nutritional reconstitution, and 24-month survival following curative gastrectomy: a randomized controlled trial.
- Psychosocial intervention to improve sleep, psychological adjustment, and quality of life in gastric cancer patients undergoing gastrectomy: a randomized controlled trial.
- Combined Effects of Psychological Intervention and Enhanced Nutritional Support on Postoperative Recovery in Gastric Cancer Patients.
- Combined sleep intervention and nutritional support to enhance postoperative recovery in gastric cancer: a prospective randomized controlled trial.
- Targeting PTBP3-Mediated Alternative Splicing of COX11 Induces Cuproptosis for Inhibiting Gastric Cancer Peritoneal Metastasis.
- Virtual NBI image synthesis using stable diffusion for enhanced recognition of early gastric cancer: a technical validation study.
- Artificial intelligence-assisted diagnosis of early gastric cancer: present practice and future prospects.
- Psychological Interventions and Sleep Improvement for Patients with Gastric Cancer: Effects on Immune Function, Inflammation, and Tumor Progression-A Randomized Controlled Trial.
- The LINC01094/miR-545-3p/SLC7A11 Signaling Axis Promotes the Development of Gastric Cancer by Regulating Cell Growth and Ferroptosis.
- Artificial intelligence-driven microRNA signature for early detection of gastric cancer: discovery and clinical functional exploration.
- JMJD3 upregulates ALOX5 to drive malignancy and concomitant ferroptosis sensitivity in gastric cancer.
- Tumor exosomal circPTBP3 drives gastric cancer peritoneal metastasis via mesothelial-mesenchymal transition.
- CST1 promoted gastric cancer development by activating the AKT pathway.
- Enhancing short-term recovery after gastric cancer surgery: an information-motivation-behavioral skills (IMB) model with nutritional support.
- HIF-1α Promotes the Confined Migration of Gastric Cancer Cells by Modulating Phosphatidylcholine Metabolism.
- N‑methyladenosine reader YTHDF2‑mediated AC026691.1 degradation promotes gastric cancer cell proliferation, migration and M2 macrophage polarization.
- CBX4 Drives Gastric Cancer Progression by Activating β-Catenin Signaling.
- FBLN2 inhibits gastric cancer proliferation and metastasis via the TGFβ/TGIF2 pathway.
- Coprevalence of modifiable gastric cancer risk factors and gastric health among Chinese high-risk groups.
- Identification of a LncRNA based CeRNA network signature to establish a prognostic model and explore potential therapeutic targets in gastric cancer.
- B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy.
- Predicting esophagojejunal anastomotic leakage in gastric cancer patients after total gastrectomy: Development and assessment of a new predictive nomogram.
- Glycolysis-related genes predict prognosis and indicate immune microenvironment features in gastric cancer.
- Differentially expressed microRNA in prognosis of gastric cancer with Lauren classification.
- Exosome-derived proteins in gastric cancer progression, drug resistance, and immune response.
- TREM1 facilitates the development of gastric cancer through regulating neutrophil extracellular traps-mediated macrophage polarization.
- From mitochondria to tumor suppression: ACAT1's crucial role in gastric cancer.
- ITGBL1 promotes anoikis resistance and metastasis in human gastric cancer via the AKT/FBLN2 axis.
- FOLR2+ macrophage depletion from intestinal metaplasia to early gastric cancer: single-cell sequencing insight into gastric cancer progression.
- BUB1 potentiates gastric cancer proliferation and metastasis by activating TRAF6/NF-κB/FGF18 through m6A modification.
- Construction of a TAN-associated risk score model with integrated multi-omics data analysis and clinical validation in gastric cancer.
- Cancer-associated fibroblasts promote proliferation, angiogenesis, metastasis and immunosuppression in gastric cancer.
- ARTN-GFRA3 axis induces epithelial-mesenchymal transition phenotypes, migration, and invasion of gastric cancer cells via KRAS signaling.
- Comparison analysis of two different types of endoscopic resection procedures in small gastric subepithelial tumours originating frommuscularis propria.
- PRSS2 regulates EMT and metastasis via MMP-9 in gastric cancer.
- Identification and validation of crucial lnc-TRIM28-14 and hub genes promoting gastric cancer peritoneal metastasis.
- The combination of preoperative fibrinogen-to-albumin ratio and postoperative TNM stage (FAR-TNM) predicts the survival in gastric cancer patients after gastrectomy.
- Feasibility evaluation of hsa_circ_0005480 as an auxiliary diagnostic and prognostic indicator for gastric cancer.
- Loss of NDUFS1 promotes gastric cancer progression by activating the mitochondrial ROS-HIF1α-FBLN5 signaling pathway.
- Over-Expression of ARID3B Suppresses Tumor Progression and Predicts Better Prognosis in Patients With Gastric Cancer.
- Gastric cancer derived exosomal THBS1 enhanced Vγ9Vδ2 T-cell function through activating RIG-I-like receptor signaling pathway in a N6-methyladenosine methylation dependent manner.
- Hsa-circ-0052001 promotes gastric cancer cell proliferation and invasion via the MAPK pathway.
- B7-H3 confers stemness characteristics to gastric cancer cells by promoting glutathione metabolism through AKT/pAKT/Nrf2 pathway.
- Identification of gastric signet ring cell carcinoma based on endoscopic images using few-shot learning.
- GADD45B regulates the carcinogenesis process of chronic atrophic gastritis and the metabolic pathways of gastric cancer.
- Clinical significance of CD155 expression and correlation with cellular components of tumor microenvironment in gastric adenocarcinoma.
- Knockdown of LINC01087 inhibits gastric cancer malignant behavior by regulating the miR-135a-5p/CAAP1 axis.
- LncRNA RUNX1-IT1 is downregulated in gastric cancer and suppresses the maturation of miR-20a by binding to its precursor.
- miRNA-223-3p regulates ECT2 to promote proliferation, invasion, and metastasis of gastric cancer through the Wnt/β-catenin signaling pathway.
- B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy.
- Integrated multi-dimensional analysis highlights DHCR7 mutations involving in cholesterol biosynthesis and contributing therapy of gastric cancer.
- MiR-200/183 family-mediated module biomarker for gastric cancer progression: an AI-assisted bioinformatics method with experimental functional survey.
- Expression and clinical significance of PD-L1 and infiltrated immune cells in the gastric adenocarcinoma microenvironment.
- An evaluation of the use of double-curved endoscopes for gastric gastrointestinal stromal tumors.
- CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1.
- TRIM69 suppressed the anoikis resistance and metastasis of gastric cancer through ubiquitin‒proteasome-mediated degradation of PRKCD.
- Learning curve for endoscopic resection of gastric gastrointestinal stromal tumors: a single-center experience.
- Risk factors for conversion from endoscopic resection to laparoscopic resection for gastric gastrointestinal stromal tumors.
- The added value of radiomics from dual-energy spectral CT derived iodine-based material decomposition images in predicting histological grade of gastric cancer.
- Activation of WNT/CTNNB1/TCF7L2 in Epstein-Barr virus-positive gastric cancer regulates epithelial mesenchymal transition.
- Circular RNA circ_0001017 Sensitizes Cisplatin-Resistant Gastric Cancer Cells to Chemotherapy by the miR-543/PHLPP2 Axis.
- MicroRNA-642b-3p functions as an oncomiR in gastric cancer by down-regulating the CUB and sushi multiple domains protein 1/smad axis.
- Risk Factors and Timing of Additional Surgery after Noncurative ESD for Early Gastric Cancer.
- Evaluation of the role of soluble B7-H3 in association with membrane B7-H3 expression in gastric adenocarcinoma.
- Gastric cancer-derived exosomal miR-135b-5p impairs the function of Vγ9Vδ2 T cells by targeting specificity protein 1.
- Cancer-associated fibroblast-released extracellular vesicles carrying miR-199a-5p induces the progression of gastric cancer through regulation of FKBP5-mediated AKT1/mTORC1 signaling pathway.
- Adenosine triphosphate-based tumor chemosensitivity assay may predict the clinical outcomes of gastric cancer patients receiving taxane-based post-operative adjuvant chemotherapy.
- Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients.
- Steroid Receptor Coactivator-1 (SRC-1) Promoted Cell Metastasis of Gastric Cancer via VEGFC Activator by NF-κB.
- miR-622 Counteracts the NUAK1-Induced Gastric Cancer Cell Proliferation and the Antioxidative Stress.
- Roux-en-Y reconstruction alleviates radical gastrectomy-induced colitis via down-regulation of the butyrate/NLRP3 signaling pathway.
- The Deubiquitinating Enzyme USP4 Functions as an Oncoprotein in Gastric Cancer and Mediates NF-κB Signaling by Regulating PRL-3 Expression.
- A vasculogenic mimicry prognostic signature associated with immune signature in human gastric cancer.
- Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.
- Diagnosis value of miR-181, miR-652, and CA72-4 for gastric cancer.
- Establishment of a Monoclonal Antibody-Based Enzyme-Linked Immunosorbent Assay to Measure Soluble B7-H5 in Patients with Cancer.
- Clinical Value of Pepsinogen in the Screening, Prevention, and Diagnosis of Gastric Cancer.
- Billroth II anastomosis maintains SMI and BMI better than Roux-en-Y anastomosis following totally laparoscopic distal gastrectomy: a propensity score-matched study.
- PRKAA1, stabilized by FTO in an m6A-YTHDF2-dependent manner, promotes cell proliferation and glycolysis of gastric cancer by regulating the redox balance.
- LINC00922 acts as a novel oncogene in gastric cancer.
- Evaluating health-related quality of life in gastric cancer patients in Suzhou, China.
- Chinese and global burdens of gastric cancer from 1990 to 2019.
- H19 promotes aerobic glycolysis, proliferation, and immune escape of gastric cancer cells through the microRNA-519d-3p/lactate dehydrogenase A axis.
- Application of Hemocoagulase Bothrops Atrox in the submucosal injection for endoscopic submucosal dissection: a preliminary trial.
- ONECUT2 which is targeted by hsa-miR-15a-5p enhances stemness maintenance of gastric cancer stem cells.
- LncRNA-HEIH is a Novel Diagnostic and Predictive Biomarker in Gastric Cancer.
- LINC02535 promotes cell growth in poorly differentiated gastric cancer.
- Circular RNA circ_HN1 facilitates gastric cancer progression through modulation of the miR-302b-3p/ROCK2 axis.
- Circular RNA hsa_circ_0072309 inhibits the proliferation, invasion and migration of gastric cancer cells via inhibition of PI3K/AKT signaling by activating PPARγ/PTEN signaling.
- SIRT5 regulates autophagy and apoptosis in gastric cancer cells.
Chinese-language papers (not in the count)5
- [Risk factors for complications of endoscopic full-thickness resection of upper gastrointestinal submucosal tumors].
- [Study of immunophenotypic characteristics, clinicopathological parameters and prognosis in gastric cancer microenvironment].
- [Analysis of efficacy and safety of a new endoscopic anastomosis clip in the treatment of defects after endoscopic full-thickness resection].
- [Gastric adenocarcinoma with enteroblastic differentiation combined with liver metastasis: report of a case].
- [Application of fecal DNA methylation biomarkers detection in gastric cancer screening].
All its trials on ClinicalTrials.gov, any status11
- AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging
- Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
- AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
- A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
- Phase IIT Trial of SNA014
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
Cancer
Retinoblastoma
视网膜母细胞瘤Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Suzhou for retinoblastoma196 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Cancer
Chordoma
脊索瘤Led 2 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 1.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Suzhou for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Cancer
Osteosarcoma
骨肉瘤Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
16 hospitals in Suzhou for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- A microsphere-vesicle hybrid system for tumor treatment through enhancement of innate and adaptive immune responses.
- GD2-mediated impairment of macrophage phagocytosis drives pulmonary metastasis in osteosarcoma.
- Targeting POLRMT by a first-in-class inhibitor IMT1 inhibits osteosarcoma cell growth in vitro and in vivo.
- Bioinformatics analysis of key pathways and genes in osteosarcoma development.
Earlier papers (2016–2020)13
- TRIM58 Interacts with Pyruvate Kinase M2 to Inhibit Tumorigenicity in Human Osteosarcoma Cells.
- LINC00612 functions as a ceRNA for miR-214-5p to promote the proliferation and invasion of osteosarcoma in vitro and in vivo.
- The Effects of Interleukin-33 (IL-33) on Osteosarcoma Cell Viability, Apoptosis, and Epithelial-Mesenchymal Transition are Mediated Through the PI3K/AKT Pathway.
- Long non-coding RNA Taurine upregulated gene 1 promotes osteosarcoma cell metastasis by mediating HIF-1α via miR-143-5p.
- Feedback modulation of endothelial cells promotes epithelial-mesenchymal transition and metastasis of osteosarcoma cells by Von Willebrand Factor release.
- MicroRNA-221 regulates osteosarcoma cell proliferation, apoptosis, migration, and invasion by targeting CDKN1B/p27.
- NEAT1 induces osteosarcoma development by modulating the miR-339-5p/TGF-β1 pathway.
- Transcription factor CEBPB inhibits the proliferation of osteosarcoma by regulating downstream target gene CLEC5A.
- MiR-183 inhibits osteosarcoma cell growth and invasion by regulating LRP6-Wnt/β-catenin signaling pathway.
- von Willebrand factor rescued by miR-24 inhibition facilitates the proliferation and migration of osteosarcoma cells in vitro.
- DownRegulated SOX4 Expression Suppresses Cell Proliferation, Migration, and Induces Apoptosis in Osteosarcoma In Vitro and In Vivo.
- Mechanisms of oxidative stress, apoptosis, and autophagy involved in graphene oxide nanomaterial anti-osteosarcoma effect.
- The lncRNA HNF1A-AS1 is a negative prognostic factor and promotes tumorigenesis in osteosarcoma.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 6 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Suzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led6
- Comparison analysis of two different types of endoscopic resection procedures in small gastric subepithelial tumours originating frommuscularis propria.
- An evaluation of the use of double-curved endoscopes for gastric gastrointestinal stromal tumors.
- Learning curve for endoscopic resection of gastric gastrointestinal stromal tumors: a single-center experience.
- Risk factors for conversion from endoscopic resection to laparoscopic resection for gastric gastrointestinal stromal tumors.
- The synergistic therapeutic effect of imatinib and protein kinase CK2 Inhibition correlates with PI3K-AKT activation in gastrointestinal stromal tumors.
- Endoscopic submucosal dissection for ultra-low large rectal stromal tumor after preoperative imatinib therapy: A case report and review.
Cancer
Neuroblastoma
神经母细胞瘤Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Suzhou for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 27 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.6%.
2 hospitals in Suzhou for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 17
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT06730256
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingSafety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT07652138
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingTreatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
- Phase
- Phase 4
- Started
- 2024-06
- Registry
- NCT06409702
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingConversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06682156
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingComparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
- Phase
- Phase 1/Phase 2
- Started
- 2019-07
- Registry
- NCT04025450
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingStudy of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2016-09
- Registry
- NCT03196414
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingA Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen
- Phase
- Phase 4
- Started
- 2026-07
- Registry
- NCT07709884
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingTo Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Registry
- NCT07454187
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Suzhou, Xi'an, Zhengzhou
- RecruitingA Phase I Study of SHR-3836 in Patients With Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-06
- Registry
- NCT07490613
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou
- RecruitingStudy to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT07529782
Age Not stated to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Suzhou, Tianjin
- RecruitingCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07555938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingA Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Registry
- NCT07760454
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Suzhou
- RecruitingA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06083207
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou
- RecruitingA Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06508983
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingA Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2023-10
- Registry
- NCT06049290
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05623020
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 2
- Started
- 2021-02
- Registry
- NCT04634552
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Suzhou, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led27
- Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone.
- Redefining multiple myeloma treatment: Advances, challenges, and future directions in immunotherapy.
- A rare case of concurrent JAK2V617F-positive essential thrombocythemia, multiple myeloma, and colorectal adenocarcinoma.
- A 2D-STI echocardiographic diagnostic model established for cardiac amyloidosis complicated with multiple myeloma.
- Effect of oral care models on the prevention of oral mucositis induced by high-doses of melphalan in patients undergoing ASCT.
- Application of individualized low-protein diet nursing for managing multiple myeloma patients with renal impairment.
- Landscapes of immunoglobulin heavy-chain gene repertoire and its cytogenetic abnormalities in Chinese patients with multiple myeloma.
- Effective Treatment with Venetoclax and Hypomethylating Agents for the Coexistence of Multiple Myeloma and Acute Myeloid Leukemia: A Case Report and Literature Review.
- MRI-based bone marrow radiomics for predicting cytogenetic abnormalities in multiple myeloma.
- Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant.
- Quantitative assessment of bone marrow infiltration and characterization of tumor burden using dual-layer spectral CT in patients with multiple myeloma.
- Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
- Autologous stem cell transplantation in multiple myeloma patients with renal impairment.
- Discriminating minimal residual disease status in multiple myeloma based on MRI: utility of radiomics and comparison of machine-learning methods.
- Increased expression of CEP72 predicts poor prognosis in multiple myeloma.
- Nursing care of patients with relapsed and refractory multiple myeloma treated with B-cell mature antigen-targeted universal chimeric antigen receptor T cells.
- Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma.
- Apparent diffusion coefficient measurements of bone marrow infiltration patterns in multiple myeloma for the assessment of tumor burden - a feasibility study.
- Cystatin C and eGFRCKD-EPI-CysC: novel biomarkers for renal impairment diagnosis and two-year progression-free survival in multiple myeloma.
- Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma.
- Successful eradication of central nervous system infiltration of primary plasma cell leukemia by temozolomide.
- Pulsatilla saponin A Induces Apoptosis and Differentiation of Myeloma Cells.
- C3a and C5a facilitates the metastasis of myeloma cells by activating Nrf2.
- Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
- Inhibition of the Otub1/c-Maf axis by the herbal acevaltrate induces myeloma cell apoptosis.
- Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement.
- Quantitative evaluation of bone marrow infiltration using dual-energy spectral computed tomography in patients with multiple myeloma.
Chinese-language papers (not in the count)19
- [Renal response and prognosis of newly diagnosed patients with multiple myeloma with renal impairment applying VRD and autologous hematopoietic stem cell transplantation].
- [Effect of Recombinant Human Thrombopoietin on Platelet Reconstitution after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma].
- [Interpretation of minimal residual disease for response evaluation in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].
- [Interpretation of risk stratification in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].
- [Efficacy and safety of VRD regimen of autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma].
- [Clinical significance and pathogenesis analysis of Moesin in multiple myeloma].
- [Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma].
- [Comparison of next-generation flow cytometry and next-generation sequencing in the assessment of minimal residual disease in multiple myeloma].
- [The Role of Whole Body DWI in the Evaluation of Bone Disease in Multiple Myeloma].
- [Efficacy of total oral regimens containing ixazomib in patients with relapsed and refractory multiple myeloma].
- [Efficacy and safety of lenalidomide combined with bortezomib and dexamethasone induction therapy in newly diagnosed patients with multiple myeloma].
- [Multiple myeloma with chromothripsis: three cases report].
- [A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].
- [The expression level of secretory mature B cell surface antigen in primary diagnosed multiple myeloma and its clinical significance].
- [Preliminary exploration of the metabolic profile and metabolic pathways in newly diagnosed multiple myeloma].
- [Application of Conditioning Regimen with Busulfan and Cyclophosphamide in Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma].
- [The Effects of Chidamide Combined with Anti-myeloma Drugs on the Proliferation and Apoptosis of Myeloma Cells].
- [Clinical Features and Prognostic Factors of Patients with Multiple Myeloma].
- [Characteristics of immunoglobulin heavy-chain gene clonal rearrangements by next-generation sequencing of patients with multiple myeloma].
All its trials on ClinicalTrials.gov, any status49
- A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen
- Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
- A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
- Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
- Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
- Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
- Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
- An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma
- Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
- CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.
- Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#
- Cohort Construction and Prognostic Model Construction for Multiple Myeloma
- A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma
- Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM
- A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
- Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
- Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients
- PDD vs PAD to Treat Initially Diagnosed MM
- Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
- To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
- Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
- A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- A Study of Daratumumab
- A Study of NINLARO® in Chinese Adults With Multiple Myeloma
- APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study of Ninlaro in Real World Clinical Practice in China
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
- Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
- Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year
- Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led 12 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 5.3%.
- Open trials as a site
- 0
- led by another institution
2 hospitals in Suzhou for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 10
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingBEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2026-09
- Registry
- NCT07854652
Age 14 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingFull-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06985485
Age 15 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingFull-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT07564453
Age 15 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingRDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
- Phase
- Phase 2
- Started
- 2024-02
- Registry
- NCT06250959
Age 15 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingDecitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06393985
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingBlinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
- Phase
- Phase 1
- Started
- 2024-04
- Registry
- NCT06507514
Age 15 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingAllogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
- Phase
- Early phase 1
- Started
- 2024-12
- Registry
- NCT06696833
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingCAV Regimen for R/R Ph- B-ALL
- Phase
- N/A
- Started
- 2022-10
- Registry
- NCT05657652
Age 15 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingU96-CAR-T-Cells For R/R B-ALL
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07511426
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingHema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
- Phase
- Early phase 1
- Started
- 2024-09
- Registry
- NCT06559644
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led12
- Shorter Duration of Blinatumomab Administration to 14 Days Has Same Efficacy and Safety Profile in Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study.
- A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphob
- Genetic and clinical characteristics of acute B-cell lymphoblastic leukemia with MEF2D fusions and report of two novel MEF2D rearrangements.
- Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease.
- Reduced-dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B-cell acute lymphoblastic leukemia.
- Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion.
- Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia.
- Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial.
- Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.
- Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
- CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and E
- Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration.
Chinese-language papers (not in the count)4
- [Clinical analysis of 7 cases of acute B cell lymphoblastic leukemia with t (17;19) (q21-22;p13)/TCF3-HLF fusion].
- [Clinical efficacy and safety of blinatumomab bridging CAR-T cell therapy in the treatment of patients with adult acute B-cell lymphoblastic leukemia].
- [Effect of MXRA7 on the Biological Functions of Acute B Lymphoblastic Leukemia Cell Line REH].
- [Ph-like B-cell acute lymphoblastic leukemia with ZEB2-JAK2 fusion gene positivity: a case report].
All its trials on ClinicalTrials.gov, any status23
- U96-CAR-T-Cells For R/R B-ALL
- BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
- Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
- Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
- Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
- Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
- Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
- Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
- CAV Regimen for R/R Ph- B-ALL
- Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL
- CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).
- ThisCART19A Bridging to alloHSCT for R/R B-ALL
- Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL
- CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
- Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia(R/R-ALL)
- CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia
- CAR-T Cell Therapy Targeting to CD19 for R/R ALL
- RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
- Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL
- A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
- CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
- Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
- CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
Blood disorders
Aplastic anaemia
再生障碍性贫血Led 11 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 2.7%.
- Open trials as a site
- 0
- led by another institution
3 hospitals in Suzhou for aplastic anaemia63 hospitals in China for aplastic anaemia
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingRomiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07400341
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingA Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
- Phase
- N/A
- Started
- 2025-10
- Registry
- NCT07499284
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow University; 2 listed hospitals as study sitesHangzhou, Suzhou, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led11
- Comparison of efficacy of eltrombopag combined with immunosuppression in the treatment of severe aplastic anemia and very severe aplastic anemia: real-world data and evidence.
- First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study.
- The Role of Pre-existing Anti-HLA Antibodies in Severe Aplastic Anemia Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation.
- Severe aplastic anemia patients with infection who received an allogeneic hematopoietic stem cell transplantation had a better chance: Long-term outcomes of a multicenter study.
- Comparison of Haploidentical Hematopoietic Stem Cell Transplant With or Without Unrelated Cord Blood Infusion in Severe Aplastic Anemia: Outcomes of a Multicenter Study.
- Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study.
- Lessons from a patient with severe aplastic anemia complicated with COVID-19.
- Outcomes of severe aplastic anemia patients with infection proceeding with allogeneic hematopoietic stem cell transplantation, versus patients without infection.
- A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia.
- Comparison of 2 Different Rabbit Anti-Thymocyte Globulin (r-ATG) Preparations: Thymocyte r-ATG versus T Lymphoblast Cell Line r-ATG in Allogeneic Hematopoietic Stem Cell Transplantation for Acquired Severe Aplastic Anemia: Propensity Score-
- First-Line Unrelated Double-Unit Umbilical Cord Blood Transplantation for Acquired Severe Aplastic Anemia.
Chinese-language papers (not in the count)3
- [The effect of cytomegalovirus and EB virus activation on hematopoietic reconstitution after intensive immunosuppressive therapy for severe aplastic anemia].
- [Positive rates and distribution characteristics of pre-existing anti-human-leukocyte-antigen antibodies in patients with different hematological diseases].
- [Sibling hematopoietic stem cell transplantation for treatment of severe aplastic anemia complicated with antiphospholipid syndrome: a case report].
All its trials on ClinicalTrials.gov, any status3
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 6 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 1.5%.
- Open trials as a site
- 0
- led by another institution
2 hospitals in Suzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingZanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
- Phase
- Phase 4
- Started
- 2025-11
- Registry
- NCT07270835
Age 14 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingDose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis
- Phase
- Phase 2/Phase 3
- Started
- 2025-06
- Registry
- NCT06951971
Age 1 year to 70 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led6
- Low-dose emapalumab combined with chemotherapy for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
- Combined emapalumab and ruxolitinib in patients with haemophagocytic Lymphohistiocytosis.
- Myelodysplastic syndrome associated-haemophagocytic lymphohistiocytosis: A retrospective study of 15 cases in a single centre.
- Successful Treatment of Refractory EBV-Associated Hemophagocytic Lymphohistiocytosis with Combined Emapalumab and PD-1 Blockade.
- An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis.
- Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis.
All its trials on ClinicalTrials.gov, any status3
More papers found outside PubMed (not counted)5
- Endothelial Activation and Stress Index (EASIX) to Predict Survival in T or NK Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis
- Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients
- Myelodysplastic Syndrome Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Study of 15 Cases in a Single Center
- The Clinical Significance and Prognostic Value of Serum Beta-2 Microglobulin in Adult Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 326 Patients
- Additional file 2 of NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis
Blood disorders
Beta thalassaemia
β 地中海贫血Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Suzhou for beta thalassaemia157 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Haemophilia A
血友病 ALed 6 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 2.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Suzhou for haemophilia A160 hospitals in China for haemophilia A
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEvaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- Phase
- Phase 2/Phase 3
- Started
- 2024-01
- Registry
- NCT06111638
Age 18 years to Not stated; men only (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Guiyang, Kunming, Suzhou, Tianjin, Wuhan, Xi’an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led6
- Macrophage membrane-encapsulated miRNA nanodelivery system for the treatment of hemophilic arthritis.
- Incidence of deep venous thrombosis in patients with hemophilia undergoing bilateral simultaneous total knee arthroplasty: a retrospective cohort study.
- Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models.
- Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C.
- The coexistence of antiβ2 glycoprotein 1 antibody antibody has no effect on hemophilia A patient.
- No Benefit to Platelet-rich Plasma Over Placebo Injections in Terms of Pain or Function in Patients with Hemophilic Knee Arthritis: A Randomized Trial.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status8
- Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)
- A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
- A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
- PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
- China ADVATE PTP Study
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led 5 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 7.8%.
- Open trials as a site
- 0
- led by another institution
1 hospital in Suzhou for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingConstruction of a Database for TTP
- Phase
- Not given
- Started
- 2022-10
- Registry
- NCT05571774
Age not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led5
- Association between N-acetylcysteine treatment and in-hospital mortality in adult patients with acquired thrombotic thrombocytopenic purpura: a cohort study.
- Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
- Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment.
- Prognostic value of dynamic cardiac biomarkers in patients with acquired refractory thrombocytopenic purpura: A retrospective study in Chinese population.
- Clinical characteristics and outcomes of adult patients with acquired thrombotic thrombocytopenic purpura: a single center retrospective study.
Chinese-language papers (not in the count)5
- [The combined regimen based on obinutuzumab plus glucocorticoid for 4 cases of relapsed iTTP].
- [Relapsed immune thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosus: a case report and literature review].
- [A combined regimen based on bortezomib and glucocorticoids for 6 patients with recurrent/refractory immune thrombotic thrombocytopenic purpura].
- [Clinical diagnosis and treatment of hereditary thrombocytopenia and purpura: a report of five cases and literature review].
- [Research Advance in Treatment of Thrombotic Thrombocytopenic Purpura --Review].
Earlier papers (2016–2020)5
- Novel mutations in ADAMTS13 CUB domains cause abnormal pre-mRNA splicing and defective secretion of ADAMTS13.
- [Effect of Recombinant Protein in the Spacer Domain on ADAMTS13 Activity].
- [Research Advances of Acquired Thrombotic Thrombocytopenic Purpura--Review].
- [The diagnostic value of PLASMIC score in the discrimination between thrombotic thrombocytopenic purpura and disseminated intravascular coagulation].
- [Progress of acquired thrombotic thrombocytopenic purpura].
All its trials on ClinicalTrials.gov, any status2
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 10 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 2.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Suzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led10
- Exploring the causal role of gut microbiota and inflammatory proteins in neuromyelitis optica spectrum disorder: A Mendelian randomization study with mediation analysis.
- Correlation of GABA+ levels in the medial prefrontal cortex and circulating follicular helper T cells in neuromyelitis optica spectrum disorder patients with cognitive impairment.
- Vitamin D status and neuromyelitis optica spectrum disease: A systematic review and meta-analysis.
- Aberrant hippocampal intrinsic morphological connectivity patterns in Neuromyelitis optica spectrum disorder with cognitive impairment: Insights from an individual-based morphological brain network.
- Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
- B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study.
- Different doses of Rituximab for the therapy of Neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
- Altered functional connectivity associated with cognitive impairment in neuromyelitis optica spectrum disorder.
- Reduced GABA levels in the medial prefrontal cortex are associated with cognitive impairment in patients with NMOSD.
- Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Myasthenia gravis
重症肌无力Led 9 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 1.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
1 hospital in Suzhou for myasthenia gravis93 hospitals in China for myasthenia gravis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingMyasthenia Gravis Registry in China
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT06241521
Age not stated (registered criteria)
Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led9
- Relative change rate of anti-acetylcholine receptor antibodies concentration Correlates with the recurrence of myasthenia gravis in AChR-Abs-positive patients.
- Expression of lymphocyte activation gene-3 on CD4+T cells is regulated by cytokine interleukin-18 in myasthenia gravis.
- The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.
- Neurometabolic and Brain Functional Alterations Associated with Cognitive Impairment in Patients with Myasthenia Gravis: A Combined 1H-MRS and fMRI Study.
- Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis.
- Association between myasthenia gravis and cognitive disorders: a PRISMA-compliant meta-analysis.
- Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis.
- Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.
- Primary biliary cirrhosis associated with myasthenia gravis after postpartum: a case report.
All its trials on ClinicalTrials.gov, any status3
Other diseases
Moyamoya disease
烟雾病Led 3 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
1 hospital in Suzhou for moyamoya disease47 hospitals in China for moyamoya disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingDevelopment and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07894107
Age 12 years to 70 years (registered criteria)
Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led3
- SDF-1/CXCR4 axis participants in the pathophysiology of adult patients with moyamoya disease.
- Data-Independent Acquisition-Based Serum Proteomic Profiling of Adult Moyamoya Disease Patients Reveals the Potential Pathogenesis of Vascular Changes.
- Assessment of Transient Cerebral Hemodynamic Disturbance via Whole-Brain Computed Tomography Perfusion After Extracranial-Intracranial Bypass in Ischemic Moyamoya Disease.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Wilson disease
肝豆状核变性(Wilson 病)Led 2 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Suzhou for Wilson disease28 hospitals in China for Wilson disease
No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Suzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Novel functional eQTL-SNPs associated with susceptibility to occupational pulmonary fibrosis: A multi-stage study.
- Urine-Derived Stem Cells Reverse Bleomycin‑Induced Experimental Pulmonary Fibrosis by Inhibition of the TGF-β1-Smad2/3 Pathway.
- IL18R1-Related Molecules as Biomarkers for Asthma Severity and Prognostic Markers for Idiopathic Pulmonary Fibrosis.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status3
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
1 hospital in Suzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingTP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Registry
- NCT06726577
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Spinal muscular atrophy
脊髓性肌萎缩症Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Suzhou for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy
No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Fabry disease
法布雷病Led 3 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 4.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Suzhou for Fabry disease85 hospitals in China for Fabry disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07187440
Age 7 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led3
- Multimodality imaging assessment of cardiac involvement in classic and late-onset Anderson-Fabry disease.
- Characteristics of atrial ventricular coupling and left atrial function impairment in early Fabry disease patients using two-dimensional speckle tracking echocardiography.
- The value of myocardial work in patients with left ventricular hypertrophy.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Suzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Behçet disease
白塞病Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Suzhou for Behçet disease149 hospitals in China for Behçet disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- Phase
- Phase 3
- Started
- 2023-11
- Registry
- NCT06145893
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Other diseases
IgA nephropathy
IgA 肾病Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Suzhou for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)3
- BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6/NF‑κB signaling pathway in glomerular mesangial cells.
- Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: a retrospective study.
- CCL20 secreted from IgA1-stimulated human mesangial cells recruits inflammatory Th17 cells in IgA nephropathy.
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Suzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status2
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Suzhou for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Getting in touch
Name card to show staff or a driver
苏州大学附属第一医院
First Affiliated Hospital of Soochow University
苏州
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR Wikidata
First Affiliated Hospital of Soochow University-; first Affiliated Hospital of Soochow University; China The First Affiliated Hospital of Soochow University; First Affiliated Hospital of Soochow University. Suzhou; Zhangjiagang First Affiliated Hospital of Soochow University